Sagimet Biosciences Inc. (SGMT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in San Mateo, CA, United States. Der aktuelle CEO ist David A. Happel.
SGMT hat IPO-Datum 2023-07-17, 14 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $177.38M.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
